Stella Pharma Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019
Period Ending	Dec '24 Dec 31, 2024	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	Mar '20 Mar 31, 2020	2019
Net Income	-	-760	-775	-764	-656	-	Upgrade
Depreciation & Amortization	-	35	35	34	31	-	Upgrade
Other Operating Activities	-	-1	-2	-	-4	-	Upgrade
Change in Accounts Receivable	-	-16	-42	38	-55	-	Upgrade
Change in Inventory	-	-175	-166	-380	-87	-	Upgrade
Change in Accounts Payable	-	26	108	-13	38	-	Upgrade
Change in Other Net Operating Assets	-	15	15	4	-39	-	Upgrade
Operating Cash Flow	-	-876	-827	-1,081	-772	-	Upgrade
Capital Expenditures	-	-10	-26	-46	-21	-	Upgrade
Sale (Purchase) of Intangibles	-	-	-3	-	-1	-	Upgrade
Investment in Securities	-	-	-	-304	-	-	Upgrade
Other Investing Activities	-	1	-	-	-	-	Upgrade
Investing Cash Flow	-	-9	-29	-350	-22	-	Upgrade
Long-Term Debt Repaid	-	-160	-160	-160	-160	-	Upgrade
Net Debt Issued (Repaid)	-	-160	-160	-160	-160	-	Upgrade
Issuance of Common Stock	-	388	451	3,616	199	-	Upgrade
Other Financing Activities	-	-	-	373	-371	-	Upgrade
Financing Cash Flow	-	228	291	3,829	-332	-	Upgrade
Miscellaneous Cash Flow Adjustments	-	-	-	-1	-2	-	Upgrade
Net Cash Flow	-	-657	-565	2,397	-1,128	-	Upgrade
Free Cash Flow	-	-886	-853	-1,127	-793	-	Upgrade
Free Cash Flow Margin	-	-329.37%	-372.49%	-1127.00%	-386.83%	-	Upgrade
Free Cash Flow Per Share	-	-28.60	-29.54	-40.13	-39.58	-	Upgrade
Cash Interest Paid	-	2	2	3	3	-	Upgrade
Cash Income Tax Paid	-	2	3	-	4	-	Upgrade
Levered Free Cash Flow	-	-612.25	-569	-828	-571.5	-	Upgrade
Unlevered Free Cash Flow	-	-611	-567.75	-826.13	-569.63	-	Upgrade
Change in Net Working Capital	265	161	70	351	153	-10	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.